Cipla falls as USFDA classifies its Bengaluru manufacturing facility as Voluntary Action Indicated
Cipla is currently trading at Rs. 1451.80, down by 20.50 points or 1.39% from its previous closing of Rs. 1472.30 on the BSE.
The scrip opened at Rs. 1478.00 and has touched a high and low of Rs. 1478.45 and Rs. 1431.70 respectively. So far 31028 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1317.60 on 10-May-2024.
Last one week high and low of the scrip stood at Rs. 1482.60 and Rs. 1406.70 respectively. The current market cap of the company is Rs. 117200.95 crore.
The promoters holding in the company stood at 29.19%, while Institutions and Non-Institutions held 54.28% and 16.52% respectively.
United States Food and Drugs Administration (USFDA) has classified routine current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s Bengaluru manufacturing facility, as Voluntary Action Indicated (VAI). USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
.jpg)
